Advances in miRNA research: Unraveling the complexities of gene regulation

Abstract

MicroRNAs (miRNAs) are crucial in diverse biological processes. In recent years, extensive research has significantly advanced our understanding of miRNA biogenesis, function, and its implications in various biological processes and diseases. In development, miRNAs precisely regulate gene expression to ensure proper organismal growth. miRNAs serve as essential modulators of cell proliferation and differentiation, thereby determining cell fate. Regarding the regulation of apoptosis, miRNAs play a significant role in controlling programmed cell death. Moreover, in metabolism, miRNAs are involved in modulating various pathways. This review examines the latest advancements in miRNA research, encompassing their biogenesis, functional roles, and involvement in various biological processes and diseases. A specific emphasis is placed on the roles of miRNAs in development, cell proliferation, apoptosis, and metabolic regulation. Additionally, cutting-edge technologies were discussed for the potential therapeutic applications of miRNA-based strategies.

Keywords

biological processes / disease / gene regulation / microRNA / therapeutics

References

[1] Han Y, Zhang G, Lv X, Ren L. Critical role of cellular microRNAs in virus infection: decades of progress. Animals Zoonoses. 2025.

[2] Hamdy NM, Zaki MB, Rizk NI, et al. Unraveling the ncRNA landscape that governs colorectal cancer: a roadmap to personalized therapeutics. Life Sci. 2024;354:122946.

[3] Lee RC, Feinbaum RL, Ambros V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.

[4] Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. Elegans. Cell. 1993;75(5):855-862.

[5] Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86-89.

[6] Edelbroek B, Kjellin J, Biryukova I, et al. Evolution of microRNAs in Amoebozoa and implications for the origin of multicellularity. Nucleic Acids Res. 2024;52(6):3121-3136.

[7] Shang R, Lee S, Senavirathne G, Lai EC. microRNAs in action: biogenesis, function and regulation. Nat Rev Genet. 2023;24(12):816-833.

[8] Morlando M, Ballarino M, Gromak N, Pagano F, Bozzoni I, Proudfoot NJ. Primary microRNA transcripts are processed co-transcriptionally. Nat Struct Mol Biol. 2008;15(9):902-909.

[9] Ballarino M, Pagano F, Girardi E, et al. Coupled RNA processing and transcription of intergenic primary microRNAs. Mol Cell Biol. 2009;29(20):5632-5638.

[10] Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18(24):3016-3027.

[11] Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415-419.

[12] Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the microprocessor complex. Nature. 2004;432(7014):231-235.

[13] Li X, Zhong S, Li C, et al. RNA helicase Brr2a promotes miRNA biogenesis by properly remodelling secondary structure of pri-miRNAs. Nat Plants. 2024;10(10):1532-1547.

[14] Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17(24):3011-3016.

[15] Lee YY, Kim H, Kim VN. Sequence determinant of small RNA production by DICER. Nature. 2023;615(7951):323-330.

[16] Nguyen TL, Nguyen TD, Bao S, Li S, Nguyen TA. The internal loops in the lower stem of primary microRNA transcripts facilitate single cleavage of human microprocessor. Nucleic Acids Res. 2020;48(5):2579-2593.

[17] Luo QJ, Zhang J, Li P, et al. RNA structure probing reveals the structural basis of Dicer binding and cleavage. Nat Commun. 2021;12(1):3397.

[18] Lee YY, Lee H, Kim H, Kim VN, Roh SH. Structure of the human DICER-pre-miRNA complex in a dicing state. Nature. 2023;615(7951):331-338.

[19] Cifuentes D, Xue H, Taylor DW, et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010;328(5986):1694-1698.

[20] Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509-524.

[21] Iwakawa HO, Tomari Y. Life of RISC: formation, action, and degradation of RNA-induced silencing complex. Mol Cell. 2022;82(1):30-43.

[22] Wei X, Ke H, Wen A, Gao B, Shi J, Feng Y. Structural basis of microRNA processing by Dicer-like 1. Nat Plants. 2021;7(10):1389-1396.

[23] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.

[24] Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019;20(1):5-20.

[25] Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci USA. 2012;109(9):3347-3352.

[26] Su N, Yu X, Duan M, Shi N. Recent advances in methylation modifications of microRNA. Genes Dis. 2025;12(1):101201.

[27] Yang N, Liu K, Yang M, Gao X. ceRNAs in cancer: mechanism and functions in a comprehensive regulatory network. J Oncol. 2021;2021:4279039.

[28] Henao-Mejia J, Williams A, Goff LA, et al. The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity. 2013;38(5):984-997.

[29] Wu F, Yang Q, Mi Y, et al. miR-29b-3p inhibitor alleviates Hypomethylation-related aberrations through a feedback loop between miR-29b-3p and DNA methylation in Cardiomyocytes. Front Cell Dev Biol. 2022;10:788799.

[30] Swahari V, Nakamura A, Hollville E, et al. MicroRNA-29 is an essential regulator of brain maturation through regulation of CH methylation. Cell Rep. 2021;35(1):108946.

[31] Takacs CM, Giraldez AJ. miR-430 regulates oriented cell division during neural tube development in zebrafish. Dev Biol. 2016;409(2):442-450.

[32] Yuan K, Ai WB, Wan LY, Tan X, Wu JF. The miR-290-295 cluster as multi-faceted players in mouse embryonic stem cells. Cell Biosci. 2017;7:38.

[33] Lipchina I, Studer L, Betel D. The expanding role of miR-302-367 in pluripotency and reprogramming. Cell Cycle. 2012;11(8):1517-1523.

[34] Baia Amaral D, Egidy R, Perera A, Bazzini AA. miR-430 regulates zygotic mRNA during zebrafish embryogenesis. Genome Biol. 2024;25(1):74.

[35] Pires CV, Freitas FC, Cristino AS, Dearden PK, Simoes ZL. Transcriptome analysis of honeybee (Apis Mellifera) haploid and diploid embryos reveals early zygotic transcription during cleavage. PLoS One. 2016;11(1):e0146447.

[36] Ji S, Chen F, Stein P, et al. OBOX regulates mouse zygotic genome activation and early development. Nature. 2023;620(7976):1047-1053.

[37] Liang HL, Nien CY, Liu HY, Metzstein MM, Kirov N, Rushlow C. The zinc-finger protein Zelda is a key activator of the early zygotic genome in drosophila. Nature. 2008;456(7220):400-403.

[38] Miao L, Tang Y, Bonneau AR, et al. The landscape of pioneer factor activity reveals the mechanisms of chromatin reprogramming and genome activation. Mol Cell. 2022;82(5):986-1002.e9.

[39] Rosa A, Brivanlou AH. Role of MicroRNAs in zygotic genome activation: modulation of mRNA during embryogenesis. Methods Mol Biol. 2017;1605:31-43.

[40] Yap XL, Chen JA. Elucidation of how the Mir-23-27-24 cluster regulates development and aging. Exp Mol Med. 2024;56(6):1263-1271.

[41] Biondic S, Petropoulos S. Evidence for functional roles of MicroRNAs in lineage specification during mouse and human preimplantation development. Yale J Biol Med. 2023;96(4):481-494.

[42] Pham JT, Gallicano GI. Specification of neural cell fate and regulation of neural stem cell proliferation by microRNAs. Am J Stem Cells. 2012;1(3):182-195.

[43] Prodromidou K, Matsas R. Species-specific miRNAs in human brain development and disease. Front Cell Neurosci. 2019;13:559.

[44] Nowakowski TJ, Rani N, Golkaram M, et al. Regulation of cell-type-specific transcriptomes by microRNA networks during human brain development. Nat Neurosci. 2018;21(12):1784-1792.

[45] Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010;115(3):163-169.

[46] Werner JH, Rosenberg JH, Um JY, Moulton MJ, Agrawal DK. Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration. Translational Research. 2019;203:73-87.

[47] Wystub K, Besser J, Bachmann A, Boettger T, Braun T. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. PLoS Genet. 2013;9(9):e1003793.

[48] Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008;22(23):3242-3254.

[49] Wei Y, Peng S, Wu M, et al. Multifaceted roles of miR-1s in repressing the fetal gene program in the heart. Cell Res. 2014;24(3):278-292.

[50] Wohl SG, Hooper MJ, Reh TA. MicroRNAs miR-25, let-7 and miR-124 regulate the neurogenic potential of Muller glia in mice. Development. 2019;146(17):dev179556.

[51] Wohl SG, Reh TA. mi<>R</>-124-9-9* potentiates <>a</scp>scl1-induced reprogramming of cultured <scp>M</scp>üller glia. Glia. 2016;64(5):743-762.

[52] Son G, Na Y, Kim Y, et al. miR-124 coordinates metabolic regulators acting at early stages of human neurogenesis. Commun Biol. 2024;7(1):1393.

[53] Todorov H, Weissbach S, Schlichtholz L, et al. Stage-specific expression patterns and co-targeting relationships among miRNAs in the developing mouse cerebral cortex. Commun Biol. 2024;7(1):1366.

[54] Jiang Y, Bian W, Chen J, et al. miRNA-137-5p improves spatial memory and cognition in Alzheimer's mice by targeting ubiquitin-specific peptidase 30. Animal Model Exp Med. 2023;6(6):526-536.

[55] Hensley AP, McAlinden A. The role of microRNAs in bone development. Bone. 2021;143:115760.

[56] Brito VGB, Bell-Hensley A, McAlinden A. MicroRNA-138: an emerging regulator of skeletal development, homeostasis, and disease. Am J Physiol Cell Physiol. 2023;325(6):C1387-C1400.

[57] Shen P, Wang B, Zheng C, Pei J, Gan D, Xie Z. LRRC75A-AS1 inhibits Chondrogenic differentiation of Bmscs via targeting the Mir-140-3p/Wnt/Beta-catenin pathway. Curr Stem Cell Res Ther. 2023;18(8):1142-1149.

[58] Miyaki S, Sato T, Inoue A, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010;24(11):1173-1185.

[59] Boateng E, Krauss-Etschmann S. miRNAs in lung development and diseases. Int J Mol Sci. 2020;21(8):2765.

[60] Wang D, Hong H, Li XX, Li J, Zhang ZQ. Involvement of Hdac3-mediated inhibition of microRNA cluster 17–92 in bronchopulmonary dysplasia development. Mol Med. 2020;26(1):99.

[61] Mulhall D, Khoshgoo N, Visser R, et al. miR-200 family expression during normal and abnormal lung development due to congenital diaphragmatic hernia at the later embryonic stage in the nitrofen rat model. Pediatr Surg Int. 2020;36(12):1429-1436.

[62] Xiong M, Jiang L, Zhou Y, et al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2012;302(3):F369-F379.

[63] Mujahid S, Nielsen HC, Volpe MV. MiR-221 and miR-130a regulate lung airway and vascular development. PLoS One. 2013;8(2):e55911.

[64] Cerqueira DM, Tayeb M, Ho J. MicroRNAs in kidney development and disease. JCI Insight. 2022;7(9):e158277.

[65] Sun P, Wang J, Ilyasova T, Shumadalova A, Agaverdiev M, Wang C. The function of miRNAs in the process of kidney development. Noncoding RNA Res. 2023;8(4):593-601.

[66] Panzade G, Srivastava T, Heruth DP, et al. Employing multi-omics analyses to understand changes during kidney development in perinatal Interleukin-6 animal model. Cells. 2024;13(19):1667.

[67] Tinel C, Lamarthee B, Callemeyn J, et al. Integrative omics analysis unravels microvascular inflammation-related pathways in kidney allograft biopsies. Front Immunol. 2021;12:738795.

[68] Sun J, Niu L, Wang Y, et al. MicroRNA-17-5p alleviates sepsis-related acute kidney injury in mice by modulating inflammation and apoptosis. Mol Med Rep. 2024;30(2):139.

[69] Hongmei H, Maojun Y, Li T, et al. Neferine inhibits the progression of diabetic nephropathy by modulating the miR-17-5p/nuclear factor E2-related factor 2 axis. J Tradit Chin Med. 2024;44(1):44-53.

[70] Saleeb R, Kim SS, Ding Q, et al. The miR-200 family as prognostic markers in clear cell renal cell carcinoma. Urol Oncol. 2019;37(12):955-963.

[71] Mahtal N, Lenoir O, Tinel C, Anglicheau D, Tharaux PL. MicroRNAs in kidney injury and disease. Nat Rev Nephrol. 2022;18(10):643-662.

[72] Floris I, Kraft JD, Altosaar I. Roles of microRNA across prenatal and postnatal periods. Int J Mol Sci. 2016;17(12):1994.

[73] Wang H, Jiang Q, Kang L, et al. Rheum officinale and salvia miltiorrhiza inhibit renal fibrosis via miR-21/PTEN/Akt signaling pathway in vitro and in vivo. J Ethnopharmacol. 2023;304:115928.

[74] Guo J. Effect of miR-21 on renal fibrosis induced by Nano-SiO(2) in diabetic nephropathy rats via PTEN/AKT pathway. J Nanosci Nanotechnol. 2021;21(2):1079-1084.

[75] Li H, Zhu X, Zhang J, Shi J. MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN/AKT pathway. Biomed Pharmacother. 2017;96:471-479.

[76] Wang T, Yu Y, Ding Y, et al. miR-3529-3p/ABCA1 axis regulates smooth muscle cell homeostasis by enhancing inflammation via JAK2/STAT3 pathway. Front Cardiovasc Med. 2024;11:1441123.

[77] Perry N, Braun R, Ben-Hamo-Arad A, et al. Integrin restriction by miR-34 protects germline progenitors from cell death during aging. Aging Cell. 2024;23(6):e14131.

[78] Srinivasan AR, Tran TT, Bonini NM. Loss of miR-34 in drosophila dysregulates protein translation and protein turnover in the aging brain. Aging Cell. 2022;21(3):e13559.

[79] Braga TV, Evangelista FCG, Gomes LC, Araujo S, Carvalho MDG, Sabino AP. Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia. Biomed Pharmacother. 2017;92:864-869.

[80] Humplikova L, Kollinerova S, Papajik T, et al. Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(4):284-293.

[81] Si W, Li Y, Shao H, et al. MiR-34a inhibits breast cancer proliferation and progression by targeting Wnt1 in Wnt/β-catenin signaling pathway. Am J Med Sci. 2016;352(2):191-199.

[82] Jigari Asl F, Khordadmehr M, Baradaran B, et al. Restoration of miR-451a-5p/miR-34a-5p could suppress the proliferation and migration of human breast cancer cells through Wnt/beta- catenin and ERK/P-ERK signaling pathways. Archives of Razi Institute. 2024;79(2):367-377.

[83] Zhang C, Kang C, You Y, et al. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol. 2009;34(6):1653-1660.

[84] Liu H, Lin H, Zhang L, et al. miR-145 and miR-143 regulate odontoblast differentiation through targeting Klf4 and Osx genes in a feedback loop. J Biol Chem. 2013;288(13):9261-9271.

[85] Kang K, Sun C, Li H, et al. N6-methyladenosine-driven miR-143/145-KLF4 circuit orchestrates the phenotypic switch of pulmonary artery smooth muscle cells. Cell Mol Life Sci. 2024;81(1):256.

[86] Liang L, Wong CM, Ying Q, et al. MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology. 2010;52(5):1731-1740.

[87] Ottaviani S, Stebbing J, Frampton AE, et al. TGF-beta induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nat Commun. 2018;9(1):1845.

[88] Ozyerli-Goknar E, Bagci-Onder T. Epigenetic deregulation of apoptosis in cancers. Cancer. 2021;13(13):3210.

[89] Bai G, Yang J, Liao W, et al. MiR-106a targets ATG7 to inhibit autophagy and angiogenesis after myocardial infarction. Animal Model Exp Med. 2024;7(4):408-418.

[90] Pileczki V, Cojocneanu-Petric R, Maralani M, Neagoe IB, Sandulescu R. MicroRNAs as regulators of apoptosis mechanisms in cancer. Clujul Medical. 2016;89(1):50-55.

[91] Jia-Yuan X, Wei S, Fang-Fang L, Zhi-Jian D, Long-He C, Sen L. miR-375 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells by suppressing PDK1. Biomed Res Int. 2020;2020:9704245.

[92] Scuruchi M, D'Ascola A, Avenoso A, et al. miR9 inhibits 6-mer HA-induced cytokine production and apoptosis in human chondrocytes by reducing NF-kB activation. Arch Biochem Biophys. 2022;718:109139.

[93] Horie T, Nishino T, Baba O, et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun. 2013;4:2883.

[94] Shao F, Wang X, Yu J, Shen K, Qi C, Gu Z. Expression of miR-33 from an SREBP2 intron inhibits the expression of the fatty acid oxidation-regulatory genes CROT and HADHB in chicken liver. Br Poult Sci. 2019;60(2):115-124.

[95] Liu W, Cao H, Ye C, et al. Hepatic miR-378 targets p110α and controls glucose and lipid homeostasis by modulating hepatic insulin signalling. Nat Commun. 2014;5(1):5684.

[96] Brozzi F. Chapter four - role of microRNA in pancreatic beta cell function. In: Santin I, Galluzzi L, eds. International Review of Cell and Molecular Biology. Academic Press; 2021:257-286.

[97] Agbu P, Carthew RW. MicroRNA-mediated regulation of glucose and lipid metabolism. Nat Rev Mol Cell Biol. 2021;22(6):425-438.

[98] Lan S, Albinsson S. Regulation of IRS-1, insulin signaling and glucose uptake by miR-143/145 in vascular smooth muscle cells. Biochem Biophys Res Commun. 2020;529(1):119-125.

[99] Chakraborty C, Doss CG, Bandyopadhyay S, Agoramoorthy G. Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes. Wiley Interdiscip Rev RNA. 2014;5:697-712.

[100] Liu YB, Dai WH, Chang JJ, Wei K. CircRNA TUBA1C promotes proliferation and glucose metabolism, and blocks apoptosis of osteosarcoma cells through sponging miR-143-3p. Pol J Pathol. 2024;75(3):215-227.

[101] Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med. 2013;19(7):892-900.

[102] Price NL, Rotllan N, Zhang X, et al. Specific disruption of Abca1 targeting largely mimics the effects of miR-33 knockout on macrophage cholesterol efflux and atherosclerotic plaque development. Circ Res. 2019;124(6):874-880.

[103] Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478(7369):404-407.

[104] Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1(2):106-113.

[105] Ramirez CM, Rotllan N, Vlassov AV, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res. 2013;112(12):1592-1601.

[106] de Aguiar Vallim TQ, Tarling EJ, Kim T, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013;112(12):1602-1612.

[107] Goedeke L, Rotllan N, Canfran-Duque A, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015;21(11):1280-1289.

[108] Zinkhan EK, Yu B, Schlegel A. Prenatal exposure to a maternal high fat diet increases hepatic cholesterol accumulation in intrauterine growth restricted rats in part through MicroRNA-122 inhibition of Cyp7a1. Front Physiol. 2018;9:645.

[109] Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121(7):2921-2931.

[110] Zhang GQ, Wang SQ, Chen Y, et al. MicroRNAs regulating mitochondrial function in cardiac diseases. Front Pharmacol. 2021;12:663322.

[111] Li W, Zhang X, Zhuang H, et al. MicroRNA-137 is a novel hypoxia-responsive microRNA that inhibits mitophagy via regulation of two mitophagy receptors FUNDC1 and NIX. J Biol Chem. 2014;289(15):10691-10701.

[112] Kim J, Fiesel FC, Belmonte KC, et al. miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1). Mol Neurodegener. 2016;11(1):55.

[113] Cheng M, Liu L, Lao Y, et al. MicroRNA-181a suppresses parkin-mediated mitophagy and sensitizes neuroblastoma cells to mitochondrial uncoupler-induced apoptosis. Oncotarget. 2016;7(27):42274-42287.

[114] Di Rita A, Maiorino T, Bruqi K, Volpicelli F, Bellenchi GC, Strappazzon F. miR-218 inhibits mitochondrial clearance by targeting PRKN E3 ubiquitin ligase. Int J Mol Sci. 2020;21(1):355.

[115] Chen L, Zhou Y, Sun Q, Zhou J, Pan H, Sui X. Regulation of autophagy by MiRNAs and their emerging roles in tumorigenesis and cancer treatment. In: Galluzzi L, Vitale I, eds. MiRNAs in Aging and Cancer. Academic Press; 2017:1-26 International Review of Cell and Molecular Biology.

[116] Abbasi A, Hosseinpourfeizi M, Safaralizadeh R. Autophagy inhibition and sensitization to cisplatin in esophageal cancer stem-like cells via all-trans retinoic acid-induced miR-30a. Curr Med Chem. 2025;32(14):2854-2885.

[117] Zou Y, Chen G, Jin J, et al. Small RNA and transcriptome sequencing reveals miRNA regulation of floral thermogenesis in Nelumbo nucifera. Int J Mol Sci. 2020;21(9):3324.

[118] Gong D, Lei J, He X, et al. Keys to the switch of fat burning: stimuli that trigger the uncoupling protein 1 (UCP1) activation in adipose tissue. Lipids Health Dis. 2024;23(1):322.

[119] Daneshyar S, Afshari S, Kadivar M, Foroutan Y. The effect of exercise training on the signaling pathway of Microrna196-a to uncoupling protein 1 in white adipose tissue. Sci Sports. 2018;33(6):380-382.

[120] Li H, Li Y, Wang Y, et al. Genome-wide landscape of miRNA-mRNA-lncRNA-circRNA ceRNA network in Nanos2 deficient mice. PLoS One. 2025;20(6):e0325260.

[121] Gao L, Zhao Y, Ma X, Zhang L. Integrated analysis of lncRNA-miRNA-mRNA ceRNA network and the potential prognosis indicators in sarcomas. BMC Med Genet. 2021;14(1):67.

[122] Siedlecki E, Remiszewski P, Stec R. The role of circHIPK3 in tumorigenesis and its potential as a biomarker in lung cancer. Cells. 2024;13(17):1483.

[123] Mao J, Lu Y. Roles of circRNAs in the progression of colorectal cancer: novel strategies for detection and therapy. Cancer Gene Ther. 2024;31(6):831-841.

[124] Ma B, Wang S, Wu W, et al. Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomed Pharmacother. 2023;162:114672.

[125] Song G, Zhou J, Song R, et al. Long noncoding RNA H19 regulates the therapeutic efficacy of mesenchymal stem cells in rats with severe acute pancreatitis by sponging miR-138-5p and miR-141-3p. Stem Cell Res Ther. 2020;11(1):420.

[126] Xu Q, Chen S, Hu Y, Huang W. Prognostic role of ceRNA network in immune infiltration of hepatocellular carcinoma. Front Genet. 2021;12:739975.

[127] Dong W, Zhan C. Bioinformatic-based mechanism identification of E2F1-related ceRNA and E2F1 immunoassays in hepatocellular carcinoma. J Gastrointest Oncol. 2022;13(4):1915-1926.

[128] Alkan AH, Cansaran-Duman D. Multifaceted interactions between lncRNA-associated ceRNA networks and small molecules in triple-negative breast cancer. Biomed Pharmacother. 2025;189:118241.

[129] Traber GM, Yu AM. RNAi-based therapeutics and novel RNA bioengineering technologies. J Pharmacol Exp Ther. 2023;384(1):133-154.

[130] Seyhan AA. Trials and tribulations of MicroRNA therapeutics. Int J Mol Sci. 2024;25(3):1469.

[131] Bourhill T, Arbuthnot P, Ely A. Successful disabling of the 5' UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics. J Virol Methods. 2016;235:26-33.

[132] Di Giorgio A, Tran TP, Duca M. Small-molecule approaches toward the targeting of oncogenic miRNAs: roadmap for the discovery of RNA modulators. Future Med Chem. 2016;8(7):803-816.

[133] Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, Wang JC. Non-viral vectors for RNA delivery. J Control Release. 2022;342:241-279.

[134] Campani V, De Rosa G, Misso G, Zarone MR, Grimaldi A. Lipid nanoparticles to deliver miRNA in cancer. Curr Pharm Biotechnol. 2016;17(8):741-749.

[135] Scholz J, Weil PP, Pembaur D, et al. An adenoviral vector as a versatile tool for delivery and expression of miRNAs. Viruses. 2022;14(9):1952.

[136] Wang Z. The Guideline of the Design and Validation of MiRNA Mimics. Vol 676. Methods in molecular biology (Clifton, NJ); 2011:211-223.

[137] Preethi KA, Lakshmanan G, Sekar D. Antagomir technology in the treatment of different types of cancer. Epigenomics. 2021;13(7):481-484.

[138] Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18(12):1121-1126.

[139] Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775-789.

[140] Matsui M, Prakash TP, Corey DR. Argonaute 2-dependent regulation of gene expression by single-stranded miRNA mimics. Mol Ther. 2016;24(5):946-955.

[141] Manikkath J, Jishnu PV, Wich PR, Manikkath A, Radhakrishnan R. Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis. Nanomedicine. 2022;17(3):181-195.

[142] Otoukesh B, Abbasi M, Gorgani HO, et al. MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma. Cancer Cell Int. 2020;20:254.

[143] Reid G, Kao SC, Pavlakis N, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8(8):1079-1085.

[144] Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11(1):25.

[145] Yang Z, Huang J, Wu X, et al. Contribution of a circulating 2'-O-methylated MicroRNA panel to the diagnosis of pancreatic ductal adenocarcinoma. J Cancer. 2024;15(6):1583-1592.

[146] Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol. 2008;18(2):89-102.

[147] Zhang D, Lee H, Zhu Z, Minhas JK, Jin Y. Enrichment of selective miRNAs in exosomes and delivery of exosomal miRNAs in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2017;312(1):L110-L121.

[148] Kang E, Kortylewski M. Lipid nanoparticle-mediated delivery of miRNA mimics to myeloid cells. Methods Mol Biol. 2023;2691:337-350.

[149] Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630-1637.

[150] Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745-752.

[151] Wang X, Liu P, Zhu H, et al. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull. 2009;80(4–5):268-273.

[152] Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275(8):44-53.

[153] Christoffersen NR, Shalgi R, Frankel LB, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010;17(2):236-245.

[154] Chim CS, Wong KY, Qi Y, et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis. 2010;31(4):745-750.

[155] Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investig New Drugs. 2017;35(2):180-188.

[156] Kumar V, Kumar V, Luo J, Mahato RI. Therapeutic potential of OMe-PS-miR-29b1 for treating liver fibrosis. Mol Ther. 2018;26(12):2798-2811.

[157] Chioccioli M, Roy S, Newell R, et al. A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. EBioMedicine. 2022;85:104304.

[158] Wang H, Zhang Y, Wu Q, Wang YB, Wang W. miR-16 mimics inhibit TGF-β1-induced epithelial-to-mesenchymal transition via activation of autophagy in non-small cell lung carcinoma cells. Oncol Rep. 2018;39(1):247-254.

[159] Ghorbani S, Talebi F, Chan WF, et al. MicroRNA-181 variants regulate T cell phenotype in the context of autoimmune Neuroinflammation. Front Immunol. 2017;8:758.

[160] Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685-689.

[161] Krutzfeldt J, Kuwajima S, Braich R, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007;35(9):2885-2892.

[162] Avitabile C, Cimmino A, Romanelli A. Oligonucleotide analogues as modulators of the expression and function of noncoding RNAs (ncRNAs): emerging therapeutics applications. J Med Chem. 2014;57(24):10220-10240.

[163] Ho PTB, Clark IM, Le LTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci. 2022;23(13):7167.

[164] He B, Zhao Z, Cai Q, et al. miRNA-based biomarkers, therapies, and resistance in cancer. Int J Biol Sci. 2020;16(14):2628-2647.

[165] Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022;38(6):613-626.

[166] Bica-Pop C, Cojocneanu-Petric R, Magdo L, Raduly L, Gulei D, Berindan-Neagoe I. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018;75(19):3539-3551.

[167] Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849-859.

[168] Kłusek M, Pawłowski B, Sienkiewicz M, Mandziuk A. Genetic technology in the targeted therapy of Alport syndrome. Qual Sport. 2025;38:57941.

[169] Fukuhara T, Matsuura Y. Role of miR-122 and lipid metabolism in HCV infection. J Gastroenterol. 2013;48(2):169-176.

[170] Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell. 2012;3(5):364-371.

[171] Stelma F, van der Ree MH, Sinnige MJ, et al. Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101. Hepatology. 2017;66(1):57-68.

[172] Ottosen S, Parsley TB, Yang L, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015;59(1):599-608.

[173] Yamamoto T, Mukai Y, Wada F, et al. Highly potent GalNAc-conjugated tiny LNA anti-miRNA-122 antisense oligonucleotides. Pharmaceutics. 2021;13(6):817.

[174] Zhang Y, Roccaro AM, Rombaoa C, et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012;120(8):1678-1686.

[175] Murugaiyan G, Beynon V, Mittal A, Joller N, Weiner HL. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2011;187(5):2213-2221.

[176] Yoo B, Greninger P, Stein GT, et al. Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin. PLoS One. 2018;13(7):e0201046.

[177] Kamel A, Owen T, Cole I, Valencia T, Lee EC. Pharmacokinetics and absorption, distribution, metabolism and excretion of RGLS4326 in mouse and monkey, an anti-miR-17 oligonucleotide for the treatment of polycystic kidney disease. Drug Metab Dispos. 2023;51(11):1536-1546.

[178] Van Meter EN, Onyango JA, Teske KA. A review of currently identified small molecule modulators of microRNA function. Eur J Med Chem. 2020;188:112008.

[179] Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl. 2008;47(39):7482-7484.

[180] Naro Y, Thomas M, Stephens MD, Connelly CM, Deiters A. Aryl amide small-molecule inhibitors of microRNA miR-21 function. Bioorg Med Chem Lett. 2015;25(21):4793-4796.

[181] Chen X, Xie B, Cao L, et al. Direct binding of microRNA-21 pre-element with Regorafenib: an alternative mechanism for anti-colorectal cancer chemotherapy? J Mol Graph Model. 2017;73:48-53.

[182] Costales MG, Suresh B, Vishnu K, Disney MD. Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA. Cell. Chem Biol. 2019;26(8):1180-1186.e5.

[183] Melo S, Villanueva A, Moutinho C, et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA. 2011;108(11):4394-4399.

[184] Shan G, Li Y, Zhang J, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol. 2008;26(8):933-940.

[185] Autin P, Blanquart C, Fradin D. Epigenetic drugs for cancer and microRNAs: a focus on histone deacetylase inhibitors. Cancer. 2019;11(10):1530.

[186] Chekhun VF, Borikun TV, Lukianova NY. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics. Exp Oncol. 2016;38(1):26-30.

[187] Diaz JP, Chirayil R, Chirayil S, Tom M, Head KJ, Luebke KJ. Association of a peptoid ligand with the apical loop of pri-miR-21 inhibits cleavage by Drosha. RNA. 2014;20(4):528-539.

[188] Yan H, Zhou M, Bhattarai U, et al. Cyclic Peptidomimetics as inhibitor for miR-155 biogenesis. Mol Pharm. 2019;16(2):914-920.

[189] Hochreuter MY, Dall M, Treebak JT, Barres R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol Metab. 2022;65:101581.

[190] Liu J, Meng T, Yuan M, et al. MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell. Int J Nanomedicine. 2016;11:6713-6725.

[191] Li W, Chen L, Gu Z, et al. Co-delivery of microRNA-150 and quercetin by lipid nanoparticles (LNPs) for the targeted treatment of age-related macular degeneration (AMD). J Control Release. 2023;355:358-370.

[192] McLendon JM, Joshi SR, Sparks J, et al. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J Control Release. 2015;210:67-75.

[193] Munir J, Yoon JK, Ryu S. Therapeutic miRNA-enriched extracellular vesicles: current approaches and future prospects. Cells. 2020;9(10):2271.

[194] Takahashi RU, Prieto-Vila M, Hironaka A, Ochiya T. The role of extracellular vesicle microRNAs in cancer biology. Clin Chem Lab Med. 2017;55(5):648-656.

[195] Ghosh R, Singh LC, Shohet JM, Gunaratne PH. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials. 2013;34(3):807-816.

[196] Mohamed A, Kunda NK, Ross K, Hutcheon GA, Saleem IY. Polymeric nanoparticles for the delivery of miRNA to treat chronic obstructive pulmonary disease (COPD). Eur J Pharm Biopharm. 2019;136:1-8.

[197] Yan H, Wang H, Zhu X, et al. Adeno-associated virus-mediated delivery of anti-miR-199a tough decoys attenuates cardiac hypertrophy by targeting PGC-1alpha. Mol Ther Nucleic Acids. 2021;23:406-417.

[198] Ogawa D, Ansari K, Nowicki MO, Salinska E, Bronisz A, Godlewski J. MicroRNA-451 inhibits migration of glioblastoma while making it more susceptible to conventional therapy. Non-coding RNA. 2019;5(1):25.

[199] Scherr M, Venturini L, Battmer K, et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 2007;35(22):e149.

[200] Dasgupta I, Chatterjee A. Recent advances in miRNA delivery systems. Methods Protoc. 2021;4(1):10.

[201] Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL, Oupicky D. Endosomolytic and tumor-penetrating mesoporous silica nanoparticles for siRNA/miRNA combination cancer therapy. ACS Appl Mater Interfaces. 2020;12(4):4308-4322.

[202] Kelly IB III, Fletcher RB, McBride JR, Weiss SM, Duvall CL. Tuning composition of polymer and porous silicon composite nanoparticles for early endosome escape of anti-microRNA peptide nucleic acids. ACS Appl Mater Interfaces. 2020;12(35):39602-39611.

[203] Orellana EA, Abdelaal AM, Rangasamy L, et al. Enhancing MicroRNA activity through increased endosomal release mediated by Nigericin. Mol Ther Nucleic Acids. 2019;16:505-518.

[204] Jakic K, Selc M, Razga F, et al. Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys. Int J Nanomedicine. 2024;19:4103-4120.

[205] Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther. 2008;19(2):111-124.

[206] Feng Y, Zou L, Yan D, et al. Extracellular MicroRNAs induce potent innate immune responses via TLR7/MyD88-dependent mechanisms. J Immunol. 2017;199(6):2106-2117.

[207] Sarvestani ST, Stunden HJ, Behlke MA, et al. Sequence-dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors. Nucleic Acids Res. 2015;43(2):1177-1188.

[208] Grimm D. The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression. Silence. 2011;2:1-6.

[209] Narayan N, Morenos L, Phipson B, et al. Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. Leukemia. 2017;31(4):808-820.

[210] Shu J, Xia Z, Li L, et al. Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs. RNA Biol. 2012;9(10):1275-1287.

[211] Schueller F, Roy S, Vucur M, Trautwein C, Luedde T, Roderburg C. The role of miRNAs in the pathophysiology of liver diseases and toxicity. Int J Mol Sci. 2018;19(1):261.

[212] Furukawa N, Sakurai F, Katayama K, Seki N, Kawabata K, Mizuguchi H. Optimization of a microRNA expression vector for function analysis of microRNA. J Control Release. 2011;150(1):94-101.

[213] Miniarikova J, Zanella I, Huseinovic A, et al. Design, characterization, and Lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease. Mol Ther Nucleic Acids. 2016;5(3):e297.

[214] Grijalvo S, Alagia A, Jorge AF, Eritja R. Covalent strategies for targeting messenger and non-coding RNAs: an updated review on siRNA, miRNA and antimiR conjugates. Genes. 2018;9(2):74.

[215] Dovgan I, Koniev O, Kolodych S, Wagner A. Antibody–oligonucleotide conjugates as therapeutic, imaging, and detection agents. Bioconjug Chem. 2019;30(10):2483-2501.

[216] Schachner-Nedherer AL, Werzer O, Kornmueller K, Prassl R, Zimmer A. Biological activity of miRNA-27a using peptide-based drug delivery systems. Int J Nanomedicine. 2019;14:7795-7808.

[217] Perepelyuk M, Sacko K, Thangavel K, Shoyele SA. Evaluation of MUC1-Aptamer functionalized hybrid nanoparticles for targeted delivery of miRNA-29b to nonsmall cell lung cancer. Mol Pharm. 2018;15(3):985-993.

[218] Hussain QM, Al-Hussainy AF, Sanghvi G, et al. Dual role of miR-155 and exosomal miR-155 in tumor angiogenesis: implications for cancer progression and therapy. Eur J Med Res. 2025;30(1):393.

[219] Kishta MS, Khamis A, Am H, Elshaar AH, Gul D. Exploring the tumor-suppressive role of miRNA-200c in head and neck squamous cell carcinoma: potential and mechanisms of exosome-mediated delivery for therapeutic applications. Transl Oncol. 2025;51:102216.

[220] Bonneau E, Neveu B, Kostantin E, Tsongalis G, De Guire V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. Ejifcc. 2019;30(2):114-127.

[221] Li H, Shan C, Zhu Y, et al. Helminth-induced immune modulation in colorectal cancer: exploring therapeutic applications. Front Immunol. 2025;16:1484686.

[222] Wang T, Liu Y, Wu X, et al. Multi-omics reveals miR-181a-5p regulates PPAR-driven lipid metabolism in oral squamous cell carcinoma: insights from CRISPR/Cas9 knockout models. J Proteome. 2025;319:105480.

[223] Tang WW, Battistone B, Bauer KM, et al. A microRNA-regulated transcriptional state defines intratumoral CD8(+) T cells that respond to immunotherapy. Cell Rep. 2025;44(2):115301.

[224] De Silva PIT, Hiniduma K, Canete R, et al. Multiplexed CRISPR assay for amplification-free detection of miRNAs. Biosensors. 2025;15(6):346.

[225] Chen X, You Q, Guo Y, et al. Mini crRNA-mediated CRISPR/Cas12a system enhanced imaging of multiple MicroRNAs in cells. Chem Biomed Imaging. 2025;3(6):369-378.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.